Join us July 12-13 in Philadelphia at the healthcare industry’s must-attend innovation event, MedCity CONVERGE.
CONVERGE gathers the entire B2B healthcare ecosystem to discuss the latest trends and leading strategies to address healthcare’s biggest challenges and opportunities. You’ll hear from healthcare experts and thought leaders from some of the most innovative organizations in the country, and come away with empowering actionable insights. View agenda here.
Register now at Early Bird rate & save $200
CONVERGE announces the following keynote talks:
IBM Watson’s Artificial Intelligence in Practice
Anil Jain, M.D., Senior VP and Chief Medical Officer, Co-Founder, IBM Watson Health Explorys will discuss IBM Watson Health’s artificial intelligence platform—what is next and how the new IBM Watson Health assets Truven Analytics, Merge Healthcare, and the Explorys unit Jain founded will use artificial intelligence to change healthcare.
Dr. Jain co-founded Explorys in 2009, based on innovations that he developed while at the Cleveland Clinic.In April 2015, Explorys was acquired by IBM as an integral component of the newly formed Watson Health business unit. Jain currently directs the informatics and analytics innovations, product management and software development, as well as leads the life sciences business unit.
Register now at Early Bird rate & save $200
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Establishing Value in Diabetes Care
Todd M. Hobbs, M.D., Chief Medical Officer, North America, Novo Nordisk will discuss the need for pharmaceutical manufacturers to establish the value of medical innovations, what “value” means in diabetes and other chronic diseases, and how the overall management of health care costs requires a multi-disciplinary, public/private, collaborative approach.
Dr. Hobbs provides overall medical guidance to Novo Nordisk’s diabetes- and obesity-related project through the optimization of relationships with top key patient and professional associations and diabetes thought leaders.
Geisinger’s Transition from Enterprise Data Warehouse to Big Data Platforms
John M. Kravitz SVP/Chief Information Officer, Geisinger Health Systems is responsible for Geisinger’s infrastructure; all mergers and acquisitions involving the implementation of systems to meet Geisinger standards; and for the regional health information exchange, KeyHIE, which currently connects more than 50 organizations throughout Pennsylvania.
Kravitz will describe how Geisinger transitioned to Big Data Platforms—the challenges, opportunities and results.
Register now at Early Bird rate & save $200
Don’t miss the industry’s premier healthcare innovation event. Join us.
###
CONVERGE is a two-day executive summit where the entire B2B healthcare ecosystem gathers—payers, providers, medtech, pharma, digital health, investors, policymakers and others—to discuss in real, actionable ways the latest strategies, innovations and technology solutions to healthcare’s biggest challenges. CONVERGE will uncover the greatest opportunities and provide the most accurate picture of where healthcare innovation is headed. Find out more here.
